{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:23:39Z","timestamp":1788218619620,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fudan Zhangjiang Clinical Medicine Innovation Fund Project","award":["KP0202118"],"award-info":[{"award-number":["KP0202118"]}]},{"name":"Integrated Traditional Chinese and Western Medicine","award":["YC-2023-0404"],"award-info":[{"award-number":["YC-2023-0404"]}]},{"name":"Fudan Good Practice Program of Teaching and Learning","award":["FD2023A227"],"award-info":[{"award-number":["FD2023A227"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-025-01985-2","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T02:58:33Z","timestamp":1752634713000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The effects of non-insulin anti-diabetic medications on the diabetic microvascular complications: a systematic review and meta-analysis of randomized clinical trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Song","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congcong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanju","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiucai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoxun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"issue":"1","key":"1985_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","volume":"9","author":"X Lu","year":"2024","unstructured":"Lu X, Xie Q, Pan X, Zhang R, Zhang X, Peng G, Zhang Y, Shen S, Tong N. Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy. Signal Transduct Target Ther. 2024;9(1):262.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"1985_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1210\/endrev\/bnad030","volume":"45","author":"MG Yu","year":"2024","unstructured":"Yu MG, Gordin D, Fu J, Park K, Li Q, King GL. Protective factors and the pathogenesis of complications in diabetes. Endocr Rev. 2024;45(2):227\u201352.","journal-title":"Endocr Rev"},{"key":"1985_CR3","doi-asserted-by":"publisher","first-page":"155332","DOI":"10.1016\/j.metabol.2022.155332","volume":"137","author":"A DeMarsilis","year":"2022","unstructured":"DeMarsilis A, Reddy N, Boutari C, Filippaios A, Sternthal E, Katsiki N, Mantzoros C. Pharmacotherapy of type 2 diabetes: an update and future directions. Metab Clin Exp. 2022;137:155332.","journal-title":"Metab Clin Exp"},{"issue":"13","key":"1985_CR4","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s40265-022-01774-4","volume":"82","author":"JH Li","year":"2022","unstructured":"Li JH, Florez JC. On the verge of precision medicine in diabetes. Drugs. 2022;82(13):1389\u2013401.","journal-title":"Drugs"},{"key":"1985_CR5","doi-asserted-by":"crossref","unstructured":"M\u0142ynarska E, Czarnik W, Dzie\u017ca N, J\u0119draszak W, Majchrowicz G, Prusinowski F, Stabrawa M, Rysz J, Franczyk B. Type 2 diabetes mellitus: new pathogenetic mechanisms, treatment and the most important complications. Int J Mol Sci. 2025; 26(3).","DOI":"10.3390\/ijms26031094"},{"key":"1985_CR6","doi-asserted-by":"crossref","unstructured":"Ratan Y, Rajput A, Pareek A, Pareek A, Singh G. Comprehending the role of metabolic and hemodynamic factors alongside different signaling pathways in the pathogenesis of diabetic nephropathy. Int J Mol Sci. 2025; 26(7).","DOI":"10.3390\/ijms26073330"},{"issue":"5","key":"1985_CR7","doi-asserted-by":"publisher","first-page":"167758","DOI":"10.1016\/j.bbadis.2025.167758","volume":"1871","author":"H Zhu","year":"2025","unstructured":"Zhu H, Li B, Huang T, Wang B, Li S, Yu K, Cai L, Ye Y, Chen S, Zhu H, et al. Update in the molecular mechanism and biomarkers of diabetic retinopathy. Biochim Biophys Acta Mol Basis Dis. 2025;1871(5):167758.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"1985_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41392-025-02175-1","volume":"10","author":"Y Yang","year":"2025","unstructured":"Yang Y, Zhao B, Wang Y, Lan H, Liu X, Hu Y, Cao P. Diabetic neuropathy: cutting-edge research and future directions. Signal Transduct Target Ther. 2025;10(1):132.","journal-title":"Signal Transduct Target Ther"},{"key":"1985_CR9","doi-asserted-by":"publisher","first-page":"l5887","DOI":"10.1136\/bmj.l5887","volume":"367","author":"R Rodriguez-Gutierrez","year":"2019","unstructured":"Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Zu\u00f1iga-Hernandez JA, McCoy RG. Benefits and harms of intensive glycemic control in patients with type 2 diabetes. BMJ. 2019;367:l5887.","journal-title":"BMJ"},{"issue":"1","key":"1985_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41392-023-01400-z","volume":"8","author":"Y Li","year":"2023","unstructured":"Li Y, Liu Y, Liu S, Gao M, Wang W, Chen K, Huang L, Liu Y. Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. Signal Transduct Target Ther. 2023;8(1):152.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"1985_CR11","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1111\/bph.12624","volume":"171","author":"D Kaiser","year":"2014","unstructured":"Kaiser D, Oetjen E. Something old, something new and something very old: drugs for treating type 2 diabetes. Br J Pharmacol. 2014;171(12):2940\u201350.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"1985_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0188-4409(00)00241-1","volume":"31","author":"N Amador-Licona","year":"2000","unstructured":"Amador-Licona N, Gu\u00edzar-Mendoza J, Vargas E, S\u00e1nchez-Camargo G, Zamora-Mata L. The short-term effect of a switch from Glibenclamide to Metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus. Arch Med Res. 2000;31(6):571\u20135.","journal-title":"Arch Med Res"},{"issue":"1","key":"1985_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12933-020-01131-3","volume":"19","author":"CS Hansen","year":"2020","unstructured":"Hansen CS, Lundby-Christiansen L, Tarnow L, Gluud C, Hedetoft C, Thorsteinsson B, Hemmingsen B, Wiinberg N, Sneppen SB, Lund SS, et al. Metformin May adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen insulin and Metformin therapy (CIMT) trial. Cardiovasc Diabetol. 2020;19(1):150.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"1985_CR14","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.2215\/CJN.09291010","volume":"6","author":"JM Lachin","year":"2011","unstructured":"Lachin JM, Viberti G, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Holman RR, Kahn SE. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin J Am Soc Nephrology: CJASN. 2011;6(5):1032\u201340.","journal-title":"Clin J Am Soc Nephrology: CJASN"},{"issue":"77","key":"1985_CR15","doi-asserted-by":"publisher","first-page":"13470","DOI":"10.14260\/jemds\/2015\/1929","volume":"4","author":"MMA Mujeeb","year":"2015","unstructured":"Mujeeb MMA, Divhare SA, EFFECT OF ADDITION OF LOSARTAN TO METFORMIN ALONE AND IN COMBINATION WITH GLIMEPIRIDE OR REPAGLINIDE IN TYPE 2 DIABETES PATIENTS WITH PROTEINURIA. J Evol Med Dent Sci-JEMDS. 2015;4(77):13470\u201383.","journal-title":"J Evol Med Dent Sci-JEMDS"},{"issue":"2","key":"1985_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0168-8227(88)80046-9","volume":"5","author":"Y Akanuma","year":"1988","unstructured":"Akanuma Y, Kosaka K, Kanazawa Y, Kasuga M, Fukuda M, Aoki S. Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas. Diabetes Res Clin Pract. 1988;5(2):81\u201390.","journal-title":"Diabetes Res Clin Pract"},{"key":"1985_CR17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1620\/tjem.141.Suppl_693","volume":"141","author":"S Baba","year":"1983","unstructured":"Baba S, Nakagawa S, Takebe K, Goto Y, Maezawa H, Takeda R, Sakamoto N, Fukui I. Comparison of Gliclazide and Glibenclamide treatment in non-insulin-dependent diabetes. Tohoku J Exp Med. 1983;141:693\u2013706.","journal-title":"Tohoku J Exp Med"},{"key":"1985_CR18","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.2147\/DMSO.S325683","volume":"14","author":"LL Song","year":"2021","unstructured":"Song LL, Kong XM, Yang ZJ, Zhang JP, Yang WY, Zhang B, Chen XP, Wang X. Acarbose reduces Low-Grade albuminuria compared to Metformin in Chinese patients with newly diagnosed type 2 diabetes. Diabetes Metab Syndr Obes. 2021;14:4451\u20138.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"12","key":"1985_CR19","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1055\/s-0032-1314836","volume":"44","author":"F Pistrosch","year":"2012","unstructured":"Pistrosch F, Passauer J, Herbrig K, Schwanebeck U, Gross P, Bornstein SR. Effect of Thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy. Horm Metab Res. 2012;44(12):914\u20138.","journal-title":"Horm Metab Res"},{"issue":"1","key":"1985_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1523-1755.2005.00416.x","volume":"68","author":"R Agarwal","year":"2005","unstructured":"Agarwal R, Saha C, Battiwala M, Vasavada N, Curley T, Chase SD, Sachs N, Semret MH. A pilot randomized controlled trial of renal protection with Pioglitazone in diabetic nephropathy. Kidney Int. 2005;68(1):285\u201392.","journal-title":"Kidney Int"},{"issue":"23\u201324","key":"1985_CR21","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00508-009-1279-3","volume":"121","author":"L Petrica","year":"2009","unstructured":"Petrica L, Petrica M, Vlad A, Dragos Jianu C, Gluhovschi G, Ianculescu C, Dumitrascu V, Giju S, Gluhovschi C, Bob F, et al. Nephro- and neuroprotective effects of Rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener Klinische Wochenschrift. 2009;121(23\u201324):765\u201375.","journal-title":"Wiener Klinische Wochenschrift"},{"issue":"2","key":"1985_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1371\/journal.pone.0264129","volume":"17","author":"CC Ho","year":"2022","unstructured":"Ho CC, Yang YS, Huang CN, Lo SC, Wang YH, Kornelius E. The efficacy of Pioglitazone for renal protection in diabetic kidney disease. PLoS ONE. 2022;17(2):14.","journal-title":"PLoS ONE"},{"issue":"11","key":"1985_CR23","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/sj.ki.5002516","volume":"72","author":"Y Miyazaki","year":"2007","unstructured":"Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int. 2007;72(11):1367\u201373.","journal-title":"Kidney Int"},{"issue":"10","key":"1985_CR24","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1053\/meta.2001.26703","volume":"50","author":"T Nakamura","year":"2001","unstructured":"Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metab Clin Exp. 2001;50(10):1193\u20136.","journal-title":"Metab Clin Exp"},{"issue":"5","key":"1985_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/dmrr.633","volume":"22","author":"T Nakamura","year":"2006","unstructured":"Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Koide H. Effect of Pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. Diabetes-Metab Res Rev. 2006;22(5):385\u20139.","journal-title":"Diabetes-Metab Res Rev"},{"issue":"1","key":"1985_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/bmjdrc-2020-001420","volume":"8","author":"G Ponirakis","year":"2020","unstructured":"Ponirakis G, Abdul-Ghani MA, Jayyousi A, Almuhannadi H, Petropoulos IN, Khan A, Gad H, Migahid O, Megahed A, DeFronzo R, et al. Effect of treatment with exenatide and Pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar study. BMJ Open Diabetes Res Care. 2020;8(1):9.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1985_CR27","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ajo.2017.12.007","volume":"187","author":"EW Gower","year":"2018","unstructured":"Gower EW, Lovato JF, Ambrosius WT, Chew EY, Danis RP, Davis MD, Goff DC Jr., Greven CM. Lack of longitudinal association between Thiazolidinediones and incidence and progression of diabetic eye disease: the ACCORD eye study. Am J Ophthalmol. 2018;187:138\u201347.","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"1985_CR28","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/dom.12348","volume":"16","author":"JF Yale","year":"2014","unstructured":"Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, Wajs E, Figueroa K, Jiang J, Law G, et al. Efficacy and safety of Canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16(10):1016\u201327.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1985_CR29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1681\/ASN.2016030278","volume":"28","author":"HJ Heerspink","year":"2017","unstructured":"Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrology: JASN. 2017;28(1):368\u201375.","journal-title":"J Am Soc Nephrology: JASN"},{"issue":"24","key":"1985_CR30","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"12","key":"1985_CR31","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.2215\/CJN.10140620","volume":"15","author":"G Bakris","year":"2020","unstructured":"Bakris G, Oshima M, Mahaffey KW, Agarwal R, Cannon CP, Capuano G, Charytan DM, de Zeeuw D, Edwards R, Greene T, et al. Effects of Canagliflozin in patients with baseline eGFR\u2009<\u200930\u00a0ml\/min per 1.73 m(2): subgroup analysis of the randomized CREDENCE trial. Clin J Am Soc Nephrology: CJASN. 2020;15(12):1705\u201314.","journal-title":"Clin J Am Soc Nephrology: CJASN"},{"issue":"5","key":"1985_CR32","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1681\/ASN.2019111168","volume":"31","author":"MJ Jardine","year":"2020","unstructured":"Jardine MJ, Zhou Z, Mahaffey KW, Oshima M, Agarwal R, Bakris G, Bajaj HS, Bull S, Cannon CP, Charytan DM, et al. Renal, cardiovascular, and safety outcomes of Canagliflozin by baseline kidney function: A secondary analysis of the CREDENCE randomized trial. J Am Soc Nephrology: JASN. 2020;31(5):1128\u201339.","journal-title":"J Am Soc Nephrology: JASN"},{"issue":"3","key":"1985_CR33","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.kint.2020.04.051","volume":"98","author":"J Li","year":"2020","unstructured":"Li J, Neal B, Perkovic V, de Zeeuw D, Neuen BL, Arnott C, Simpson R, Oh R, Mahaffey KW, Heerspink HJL. Mediators of the effects of Canagliflozin on kidney protection in patients with type 2 diabetes. Kidney Int. 2020;98(3):769\u201377.","journal-title":"Kidney Int"},{"issue":"1","key":"1985_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000519920","volume":"53","author":"D Lam","year":"2022","unstructured":"Lam D, Nadkarni GN, Mosoyan G, Neal B, Mahaffey KW, Rosenthal N, Hansen MK, Heerspink HJL, Fleming F, Coca SG. Clinical utility of kidneyintelx in early stages of diabetic kidney disease in the CANVAS trial. Am J Nephrol. 2022;53(1):21\u201331.","journal-title":"Am J Nephrol"},{"issue":"1","key":"1985_CR35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/jdi.13624","volume":"13","author":"T Wada","year":"2022","unstructured":"Wada T, Mori-Anai K, Kawaguchi Y, Katsumata H, Tsuda H, Iida M, Arakawa K, Jardine MJ. Renal, cardiovascular and safety outcomes of Canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: results from the Canagliflozin and renal events in diabetes with established nephropathy clinical evaluation trial. J Diabetes Invest. 2022;13(1):54\u201364.","journal-title":"J Diabetes Invest"},{"issue":"11","key":"1985_CR36","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1093\/ndt\/gfx350","volume":"33","author":"CCJ Dekkers","year":"2018","unstructured":"Dekkers CCJ, Wheeler DC, Sjostrom CD, Stefansson BV, Cain V, Heerspink HJL. Effects of the sodium-glucose co-transporter 2 inhibitor Dapagliflozin in patients with type 2 diabetes and stages 3b-4 chronic kidney disease. Nephrol Dial Transpl. 2018;33(11):2005\u201311.","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"1985_CR37","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S2213-8587(19)30086-5","volume":"7","author":"C Pollock","year":"2019","unstructured":"Pollock C, Stef\u00e1nsson B, Reyner D, Rossing P, Sj\u00f6str\u00f6m CD, Wheeler DC, Langkilde AM, Heerspink HJL. Albuminuria-lowering effect of Dapagliflozin alone and in combination with saxagliptin and effect of Dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(6):429\u201341.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"1985_CR38","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, et al. Effects of Dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"1985_CR39","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1681\/ASN.2021020167","volume":"32","author":"GM Chertow","year":"2021","unstructured":"Chertow GM, Vart P, Jongs N, Toto RD, Gorriz JL, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Sj\u00f6str\u00f6m CD, et al. Effects of Dapagliflozin in stage 4 chronic kidney disease. J Am Soc Nephrology: JASN. 2021;32(9):2352\u201361.","journal-title":"J Am Soc Nephrology: JASN"},{"issue":"11","key":"1985_CR40","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","volume":"9","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink HJL, Jongs N, Chertow GM, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sj\u00f6str\u00f6m CD, Stefansson BV, Toto RD, et al. Effect of Dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):743\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"1985_CR41","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.2337\/dc21-0076","volume":"44","author":"O Mosenzon","year":"2021","unstructured":"Mosenzon O, Wiviott SD, Heerspink HJL, Dwyer JP, Cahn A, Goodrich EL, Rozenberg A, Schechter M, Yanuv I, Murphy SA, et al. The effect of Dapagliflozin on albuminuria in DECLARE-TIMI 58. Diabetes Care. 2021;44(8):1805\u201315.","journal-title":"Diabetes Care"},{"issue":"8","key":"1985_CR42","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1111\/dom.14410","volume":"23","author":"CC van Ruiten","year":"2021","unstructured":"van Ruiten CC, van der Aart AB, RG IJ, Nieuwdorp M, Hoogenberg K, van Raalte DH, Heerspink HJL. Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial. Diabetes Obes Metab. 2021;23(8):1851\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1985_CR43","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","volume":"9","author":"N Jongs","year":"2021","unstructured":"Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, Rossing P, Sj\u00f6str\u00f6m CD, Stefansson BV, Toto RD, et al. Effect of Dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):755\u201366.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"1985_CR44","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2215\/CJN.14901219","volume":"15","author":"A Levin","year":"2020","unstructured":"Levin A, Perkovic V, Wheeler DC, Hantel S, George JT, von Eynatten M, Koitka-Weber A, Wanner C. Empagliflozin and cardiovascular and kidney outcomes across KDIGO risk categories: post hoc analysis of a randomized, Double-Blind, Placebo-Controlled, multinational trial. Clin J Am Soc Nephrology: CJASN. 2020;15(10):1433\u201344.","journal-title":"Clin J Am Soc Nephrology: CJASN"},{"issue":"3","key":"1985_CR45","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/jdi.12971","volume":"10","author":"T Kadowaki","year":"2019","unstructured":"Kadowaki T, Nangaku M, Hantel S, Okamura T, von Eynatten M, Wanner C, Koitka-Weber A. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: results from the EMPA-REG OUTCOME(\u00ae) trial. J Diabetes Invest. 2019;10(3):760\u201370.","journal-title":"J Diabetes Invest"},{"key":"1985_CR46","doi-asserted-by":"crossref","unstructured":"Ruggenenti P, Kraus BJ, Inzucchi SE, Zinman B, Hantel S, Mattheus M, von Eynatten M, Remuzzi G, Koitka-Weber A, Wanner C. Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes. EClinicalMedicine. 2022; 43.","DOI":"10.1016\/j.eclinm.2021.101240"},{"issue":"12","key":"1985_CR47","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1111\/dom.14158","volume":"22","author":"C Wanner","year":"2020","unstructured":"Wanner C, Inzucchi SE, Zinman B, Koitka-Weber A, Mattheus M, George JT, von Eynatten M, Hauske SJ, Investigators E-RO. Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: insights from theEMPA-REG outcometrial. Diabetes Obes Metab. 2020;22(12):2335\u201347.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1985_CR48","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1007\/s00125-021-05407-5","volume":"64","author":"DZI Cherney","year":"2021","unstructured":"Cherney DZI, Charbonnel B, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, Shih WJ, Frederich R, Maldonado M, Pong A, et al. Effects of Ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia. 2021;64(6):1256\u201367.","journal-title":"Diabetologia"},{"issue":"9","key":"1985_CR49","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.2215\/CJN.01130121","volume":"16","author":"DZI Cherney","year":"2021","unstructured":"Cherney DZI, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, Frederich R, Maldonado M, Liu CC, Liu J, Pong A, et al. Ertugliflozin and slope of chronic eGFR: prespecified analyses from the randomized VERTIS CV trial. Clin J Am Soc Nephrology: CJASN. 2021;16(9):1345\u201354.","journal-title":"Clin J Am Soc Nephrology: CJASN"},{"key":"1985_CR50","doi-asserted-by":"crossref","unstructured":"Liao J, Kang A, Xia C, Young T, Di Tanna GL, Arnott C, Pollock C, Krishnan AV, Agarwal R, Bakris G et al. The impact of Canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. Diabetes Metabolism. 2022;48(4).","DOI":"10.1016\/j.diabet.2022.101331"},{"issue":"11","key":"1985_CR51","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1111\/dom.12983","volume":"19","author":"SS Engel","year":"2017","unstructured":"Engel SS, Suryawanshi S, Stevens SR, Josse RG, Cornel JH, Jakuboniene N, Riefflin A, Tankova T, Wainstein J, Peterson ED, et al. Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. Diabetes Obes Metab. 2017;19(11):1587\u201393.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1985_CR52","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/dom.12281","volume":"16","author":"PH Groop","year":"2014","unstructured":"Groop PH, Del Prato S, Taskinen MR, Owens DR, Gong Y, Crowe S, Patel S, von Eynatten M, Woerle HJ. Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. Diabetes Obes Metab. 2014;16(6):560\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1985_CR53","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.2337\/dc14-1684","volume":"38","author":"M Laakso","year":"2015","unstructured":"Laakso M, Rosenstock J, Groop PH, Barnett AH, Gallwitz B, Hehnke U, Tamminen I, Patel S, von Eynatten M, Woerle HJ. Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial. Diabetes Care. 2015;38(2):e15\u201317.","journal-title":"Diabetes Care"},{"issue":"8","key":"1985_CR54","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.2337\/dc20-0279","volume":"43","author":"V Perkovic","year":"2020","unstructured":"Perkovic V, Toto R, Cooper ME, Mann JFE, Rosenstock J, McGuire DK, Kahn SE, Marx N, Alexander JH, Zinman B, et al. Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial. Diabetes Care. 2020;43(8):1803\u201312.","journal-title":"Diabetes Care"},{"issue":"4","key":"1985_CR55","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/dom.12863","volume":"19","author":"SA Yoon","year":"2017","unstructured":"Yoon SA, Han BG, Kim SG, Han SY, Jo YI, Jeong KH, Oh KH, Park HC, Park SH, Kang SW, et al. Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study). Diabetes Obes Metab. 2017;19(4):590\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1985_CR56","first-page":"2357","volume":"36","author":"YR Chung","year":"2016","unstructured":"Chung YR, Park SW, Kim JW, Kim JH, Lee K. PROTECTIVE EFFECTS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON PROGRESSION OF DIABETIC RETINOPATHY IN PATIENTS WITH TYPE 2 DIABETES. Retin-J Retin Vitr Dis. 2016;36(12):2357\u201363.","journal-title":"Retin-J Retin Vitr Dis"},{"issue":"10193","key":"1985_CR57","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Ryd\u00e9n L, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet (London England). 2019;394(10193):131\u20138.","journal-title":"Lancet (London England)"},{"issue":"9","key":"1985_CR58","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","volume":"377","author":"JFE Mann","year":"2017","unstructured":"Mann JFE, Orsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornoe K, Zinman B, Buse JB, Investigators LSC. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839\u201348.","journal-title":"N Engl J Med"},{"issue":"3","key":"1985_CR59","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/dom.12816","volume":"19","author":"KR Tuttle","year":"2017","unstructured":"Tuttle KR, McKinney TD, Davidson JA, Anglin G, Harper KD, Botros FT. Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials. Diabetes Obes Metab. 2017;19(3):436\u201341.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"1985_CR60","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jdiacomp.2015.07.013","volume":"29","author":"M Jaiswal","year":"2015","unstructured":"Jaiswal M, Martin CL, Brown MB, Callaghan B, Albers JW, Feldman EL, Pop-Busui R. Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study. J Diabetes Complicat. 2015;29(8):1287\u201394.","journal-title":"J Diabetes Complicat"},{"issue":"1","key":"1985_CR61","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1089\/jop.2021.0055","volume":"38","author":"TA Nielsen","year":"2022","unstructured":"Nielsen TA, Sega R, Andersen CU, Vorum H, Drewes AM, Jakobsen PE, Brock B, Brock C. Liraglutide treatment does not induce changes in the peripapillary retinal nerve Fiber layer thickness in patients with diabetic retinopathy. J Ocular Pharmacol Ther. 2022;38(1):114\u201321.","journal-title":"J Ocular Pharmacol Ther"},{"issue":"4","key":"1985_CR62","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/dom.13172","volume":"20","author":"T Vilsboll","year":"2018","unstructured":"Vilsboll T, Bain SC, Leiter LA, Lingvay I, Matthews D, Simo R, Helmark IC, Wijayasinghe N, Larsen M. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889\u201397.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"1985_CR63","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamainternmed.2018.3034","volume":"178","author":"HY Chang","year":"2018","unstructured":"Chang HY, Singh S, Mansour O, Baksh S, Alexander GC. Association between Sodium-Glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes. JAMA Intern Med. 2018;178(9):1190\u20138.","journal-title":"JAMA Intern Med"},{"key":"1985_CR64","doi-asserted-by":"publisher","first-page":"m2812","DOI":"10.1136\/bmj.m2812","volume":"370","author":"M Fralick","year":"2020","unstructured":"Fralick M, Kim SC, Schneeweiss S, Everett BM, Glynn RJ, Patorno E. Risk of amputation with Canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020;370:m2812.","journal-title":"BMJ"},{"issue":"7","key":"1985_CR65","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"18","key":"1985_CR66","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1093\/eurheartj\/ehaa956","volume":"42","author":"SK Paul","year":"2021","unstructured":"Paul SK, Bhatt DL, Montvida O. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study. Eur Heart J. 2021;42(18):1728\u201338.","journal-title":"Eur Heart J"},{"key":"1985_CR67","doi-asserted-by":"publisher","first-page":"k4365","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda P, Svanstr\u00f6m H, Melbye M, Eliasson B, Svensson AM, Franz\u00e9n S, Gudbj\u00f6rnsdottir S, Hveem K, Jonasson C, Pasternak B. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365.","journal-title":"BMJ"},{"key":"1985_CR68","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.metabol.2019.04.008","volume":"96","author":"N Katsiki","year":"2019","unstructured":"Katsiki N, Dimitriadis G, Hahalis G, Papanas N, Tentolouris N, Triposkiadis F, Tsimihodimos V, Tsioufis C, Mikhailidis DP, Mantzoros C. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence. Metab Clin Exp. 2019;96:92\u2013100.","journal-title":"Metab Clin Exp"},{"issue":"24","key":"1985_CR69","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/eurheartj\/ehad276","volume":"44","author":"JH Butt","year":"2023","unstructured":"Butt JH, Kondo T, Yang M, Jhund PS, Docherty KF, Vaduganathan M, Claggett BL, Hernandez AF, Lam CSP, Inzucchi SE, et al. Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. Eur Heart J. 2023;44(24):2170\u201383.","journal-title":"Eur Heart J"},{"issue":"11","key":"1985_CR70","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1161\/CIRCULATIONAHA.123.065517","volume":"149","author":"AM Billing","year":"2024","unstructured":"Billing AM, Kim YC, Gullaksen S, Schrage B, Raabe J, Hutzfeldt A, Demir F, Kovalenko E, Lass\u00e9 M, Dugourd A, et al. Metabolic communication by SGLT2 Inhibition. Circulation. 2024;149(11):860\u201384.","journal-title":"Circulation"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-01985-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-025-01985-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-01985-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T12:38:54Z","timestamp":1757248734000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-025-01985-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1985"],"URL":"https:\/\/doi.org\/10.1186\/s12902-025-01985-2","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"179"}}